BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32560601)

  • 1. Effective Pharmacophore for CDC25 Phosphatases Enzyme Inhibitors: Newly Synthesized Bromothiazolopyrimidine Derivatives.
    El-Shahat M; Salama MAM; El-Farargy AF; Ali MM; Ahmed DM
    Mini Rev Med Chem; 2021; 21(1):118-131. PubMed ID: 32560601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors.
    Kolb S; Mondésert O; Goddard ML; Jullien D; Villoutreix BO; Ducommun B; Garbay C; Braud E
    ChemMedChem; 2009 Apr; 4(4):633-48. PubMed ID: 19212959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based development of novel triazoles and related thiazolotriazoles as anticancer agents and Cdc25A/B phosphatase inhibitors. Synthesis, in vitro biological evaluation, molecular docking and in silico ADME-T studies.
    Rostom SAF; Badr MH; Abd El Razik HA; Ashour HMA
    Eur J Med Chem; 2017 Oct; 139():263-279. PubMed ID: 28803043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries.
    Jing L; Wu G; Hao X; Olotu FA; Kang D; Chen CH; Lee KH; Soliman MES; Liu X; Song Y; Zhan P
    Eur J Med Chem; 2019 Dec; 183():111696. PubMed ID: 31541869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel bis-thiazolone derivatives as micromolar CDC25 phosphatase inhibitors: effect of dimerisation on phosphatase inhibition.
    Sarkis M; Tran DN; Kolb S; Miteva MA; Villoutreix BO; Garbay C; Braud E
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7345-50. PubMed ID: 23141909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid discovery of triazolobenzylidene-thiazolopyrimidines (TBTP) as CDC25 phosphatase inhibitors by parallel click chemistry and in situ screening.
    Duval R; Kolb S; Braud E; Genest D; Garbay C
    J Comb Chem; 2009; 11(6):947-50. PubMed ID: 19835352
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.
    Cai J; Zhang S; Zheng M; Wu X; Chen J; Ji M
    Bioorg Med Chem Lett; 2012 Jan; 22(2):806-10. PubMed ID: 22217877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of novel thiazolyl-pyrimidines and their anticancer activity in vitro.
    Shi HB; Li HB; Lu KQ; Zhu XR; Hu WX; Pei W
    Arch Pharm (Weinheim); 2011 Oct; 344(10):675-83. PubMed ID: 21984017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and anticancer activity of new thiazolo[3,2-a]pyrimidines: DNA binding and molecular modeling study.
    Hassan GS; El-Messery SM; Abbas A
    Bioorg Chem; 2017 Oct; 74():41-52. PubMed ID: 28750204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-pot synthesis of thiazolo[3,2-a]pyrimidine derivatives, their cytotoxic evaluation and molecular docking studies.
    Sekhar T; Thriveni P; Venkateswarlu A; Daveedu T; Peddanna K; Sainath SB
    Spectrochim Acta A Mol Biomol Spectrosc; 2020 Apr; 231():118056. PubMed ID: 32006911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2,4-Dihydroxychalcone derivatives as novel potent cell division cycle 25B phosphatase inhibitors and protein tyrosine phosphatase 1B inhibitors.
    Xie C; Sun Y; Pan CY; Tang LM; Guan LP
    Pharmazie; 2014 Apr; 69(4):257-62. PubMed ID: 24791588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
    Schepetkin IA; Karpenko AS; Khlebnikov AI; Shibinska MO; Levandovskiy IA; Kirpotina LN; Danilenko NV; Quinn MT
    Eur J Med Chem; 2019 Dec; 183():111719. PubMed ID: 31563013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and selective Cdc25 phosphatase inhibitors via rapid assembly and in situ screening of Quinonoid-focused libraries.
    Tao Y; Hao X; Jing L; Sun L; Cherukupalli S; Liu S; Wu G; Xu S; Zhang X; Shi X; Song Y; Liu X; Zhan P
    Bioorg Chem; 2021 Oct; 115():105254. PubMed ID: 34426152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases.
    Huang W; Li J; Zhang W; Zhou Y; Xie C; Luo Y; Li Y; Wang J; Li J; Lu W
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1905-8. PubMed ID: 16434190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.
    Zhou W; Huang A; Zhang Y; Lin Q; Guo W; You Z; Yi Z; Liu M; Chen Y
    Eur J Med Chem; 2015; 96():269-80. PubMed ID: 25899332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
    Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
    Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and structural optimization of pyrazole derivatives as novel inhibitors of Cdc25B.
    Chen HJ; Liu Y; Wang LN; Shen Q; Li J; Nan FJ
    Bioorg Med Chem Lett; 2010 May; 20(9):2876-9. PubMed ID: 20363629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel 2,4-bismorpholinothieno[3,2-d]pyrimidine and 2-morpholinothieno[3,2-d]pyrimidinone derivatives as potent antitumor agents.
    Ye T; Han Y; Wang R; Yan P; Chen S; Hou Y; Zhao Y
    Bioorg Chem; 2020 Jun; 99():103796. PubMed ID: 32283346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.